# US 2021/0079079 A1 · Systems and methods for local modulation of wnt signaling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079079 A1
- Document ID: US20210079079A1
- Status: Published application
- Kind: A1
- Application number: 17/049,567
- Filed: 2019-05-01
- Published: 2021-03-18
- Earliest claimed: 2018-05-02
- Assignees: Ortheus, Inc.
- Applicants: Ortheus, Inc.
- Inventors: Paul Kostenuik; Faisal Mirza; Michael Collins
- Web page: https://patentgrep.com/patent/US20210079079A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 35/19: Platelets; Megacaryocytes
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61K 38/1709: {from mammals}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A system is provided including a promoter of Wnt signaling and an autologous body material (ABM) or its functional equivalent. The promoter of Wnt signaling can be an agent that inhibits the activity or bioavailability of DKK1 protein, e.g., an anti-DKK1 antibody (DKAB). The promoter of Wnt signaling can also be an agent that initiates, promotes, or potentiates Wnt signaling by means other than inhibition of DKK1. The ABM in some embodiments are prepared to remove DKK1 or an antagonist of Wnt signaling. A process of locally administering the system is also provided to enhance the intended or ancillary effects of the ABM. The system is useful in promoting the growth of new bone or the augmentation, reconstitution, regeneration, fusion, fixation, repair, or healing of damaged, injured or otherwise deficient bone in therapeutically or esthetically desirable locations, or for promoting hair growth or wound healing.

## Claims

### Claim 1

A composition comprising:
a promoter of Wnt signaling; and
an autologous body material, an allogeneic body material, a xenogeneic body material or a functional equivalent thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the promoter of Wnt signaling comprises an anti-Dickkopf-related protein 1 (DKK1) antibody (DKAB) or other inhibitor of Dickkopf-related protein 1 (DKK1); scFv-DKK1c or other Wnt receptor heterodimerizing agent; a sclerostin antibody or other inhibitor of sclerostin; Wnt3a, liposomal Wnt3a or other recombinant Wnts that promote Wnt signaling; R-Spondin; lithium; WAY316606; LY2090314; promoters of LRP5, LRP6 or frizzled receptor signaling; an inhibitor of Kremen function; an inhibitor of Wnt inhibitory factor-1 (WIF-1); an inhibitor of Wise/SOSTDC; or an inhibitor of secreted frizzled-related proteins (sFRPs).

### Claim 3 (depends on 1)

The composition of claim 1, wherein the autologous body material comprises platelet-rich plasma (PRP), platelet-rich fibrin (PRF), bone autograft, surgical bone, surgical blood, peripheral blood, hematoma, reamer-irrigator aspirate, plasma, platelet-poor plasma (PPP), bone marrow aspirate (BMA), bone marrow cell aspirate concentrate, or adipose derived ABM or a combination thereof, wherein the PRP, blood, plasma, PPP, and BMA may be in unclotted or clotted forms.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the promoter of Wnt signaling pathway is combined with, mixed with, entrapped in, encapsulated in, delivered alongside or is within the autologous, allogeneic or xenogeneic body material.

### Claim 5 (depends on 2)

The composition of claim 2, wherein the promoter of Wnt signaling pathway is in a form of lyophilized, crystallized, liquid, frozen, gel, powder, paste or emulsion, prior to being combined with, mixed with, entrapped in, encapsulated in, delivered alongside or within the autologous, allogeneic or xenogeneic body material.

### Claim 6 (depends on 1)

The composition of claim 1, comprising an anti-DKK1 antibody and platelet-rich fibrin or platelet-rich plasma.

### Claim 7 (depends on 1)

The composition of claim 1, comprising an anti-DKK1 antibody and autologous bone graft or bone marrow, or bone marrow aspirate, or bone marrow aspirate concentrate, or reamer irrigated aspirate or any combination thereof.

### Claim 8 (depends on 1)

The composition of claim 1, comprising an anti-DKK1 antibody and autologous plasma.

### Claim 9 (depends on 1)

The composition of claim 1, comprising an anti-DKK1 antibody and autologous fibrin gel combined with a bone graft material.

### Claim 10

A method of treating, or reducing the severity of, or reducing the likelihood of developing, or accelerating the healing of a defect or deficiency in a mammal by administering a promoter of Wnt signaling directly to locally expressed autologous body materials.

### Claim 11 (depends on 1)

A method for treating, or reducing the severity of, or reducing the likelihood of developing, or accelerating the healing of a defect or deficiency in a mammal using the composition of claim 1, comprising:
obtaining a volume of an autologous body material from a mammal;
preparing the autologous body material;
adding a promoter of Wnt signaling to the prepared autologous body material to form a combined material; and
administering the combined material to the site of the defect or deficiency.

### Claim 12 (depends on 11)

The method of claim 11, wherein a single-use kit is used in adding the promoter of Wnt signaling to the prepared autologous body material and further optionally in storing the combined material.

### Claim 13 (depends on 12)

The method of claim 12, wherein the single-use kit comprises a sterile, closed system.

### Claim 14 (depends on 1)

A device comprising the composition of claim 1.

### Claim 15 (depends on 14)

The device of claim 14, further comprising an effective amount of an agent to induce platelet activation, fibrin formation, fibrin crosslinking or fibrin clot formation, which comprises one or more coagulant factors comprising calcium chloride, thrombin, prothrombin complex concentrate, chitosan, tissue factors, glass surface and silica.

### Claim 16 (depends on 14)

The device of claim 14, adapted for a filler, a coating or an implant, wherein the implant comprises collagen sponge, a hydroxyapatite-containing sponge, a strip, a block, a plug, a bone graft, a dental implant, a craniofacial implant, an orthopedic implant, a prosthesis, a fusion cage, a screw, a plate, a pin, a button, a disc, a wire, or a rod.

### Claim 17 (depends on 1)

A method of treating or reducing the severity of, or reducing the likelihood of developing, or accelerating the healing of a bone-related disease or condition, or cosmetically changing a bone structure in a subject, comprising:
administering the composition of claim 1 or implanting a device comprising said composition,
wherein the growth of new bone is promoted, or that damaged, injured or deficient bone is augmented, reconstituted, regenerated, fused, repaired, or healed.

### Claim 18 (depends on 17)

The method of claim 17, wherein the disease or condition, or the bone structure change, comprises implant fixation, fracture repair, arthrodesis, extraction socket preservation, spinal fusion, bone healing, tendon or ligament reconstruction in bone, distraction osteogenesis, esthetic appearance and geometry, bone cavity defects, or traumatic bone loss.

### Claim 19 (depends on 18)

The method of claim 18, wherein the composition is administered locally at a site of the disease or condition.

### Claim 20 (depends on 1)

A method of treating or reducing the severity of, or reducing the likelihood of developing, or accelerating the healing of a wound related disease or condition, or esthetically changing the skin tissue in a subject, comprising:
administering the composition of claim 1 or implanting a device comprising said composition,
wherein the growth of new tissue is promoted, or a damaged, injured or deficient tissue is augmented, reconstituted, regenerated, repaired, or healed.

### Claim 21 (depends on 1)

A method of treating or reducing the severity of, or reducing the likelihood of developing, or accelerating the reversal of a hair disease or disorder or condition, or esthetically changing the hair in a subject, comprising:
administering the composition of claim 1 or implanting a device comprising said composition,
wherein the growth or thickness of new hair is promoted, or a damaged, injured or deficient hair follicle is augmented, reconstituted, regenerated, repaired, or healed.

### Claim 22 (depends on 17)

The method of claim 17, further comprising removing, reducing, or rendering inactive DKK1 or another inhibitor of Wnt signaling from the autologous body material prior to the administration or the implantation to the subject.

### Claim 23

A composition or a device comprising a composition, wherein the composition comprises an autologous body material (ABM), or a functional equivalent thereof, wherein DKK1 or one or more other endogenous extracellular Wnt antagonists has been removed from or reduced in the ABM, wherein the Wnt antagonists comprise DKK1, sclerostin, secreted frizzled-related proteins (sFRPs), Wnt inhibitory factor 1 (WIF-1), Wise, or a combination thereof.

### Claim 24 (depends on 23)

A method of preparing the composition of claim 23, wherein the DKK1 or other Wnt antagonist has been removed or reduced prior to, during, or after the preparation, the method comprising: obtaining an autologous body material (ABM) from a mammal, and isolating, concentrating, activating, polymerizing, cross-linking, and/or purifying the ABM.

### Claim 25 (depends on 24)

A method of claim 24 wherein the DKK1 or other Wnt antagonist is removed or reduced using an apparatus that binds, filters, adheres to, eliminates, destroys, depletes or renders inactive DKK1 or other Wnt antagonists.

### Claim 26 (depends on 24)

A method of claim 24 wherein platelets, growth factors, leucocytes or a combination thereof are substantially retained in the composition.

### Claim 27

(canceled)

### Claim 28

(canceled)
